Enschede

• SAFEST Not authorised
  2022-502059-79-00 6 Ischemic stroke or transient ischemic attack
• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc … Unknown
  2022-502779-40-99 5 Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• Avelumab Short Maintenance Trial Pending
  2024-512975-11-01 11 urothelial cancer
• Filgotinib bridging in newly diagnosed rheumatoid arthritis patients (FAST RA trial); A pragmatic randomized controlled non-inferiority low … Pending
  2024-517112-30-00 6 Rheumatoid arthritis
• Adjuvant Pembrolizumab in patients with early-stage triple negative breast cancer with residual disease after treatment with chemotherapy an … Pending
  2025-524229-41-00 5 Triple negative breast cancer
• HO182 CLL: Treatment of patients with chronic lymphocytic leukemia (CLL) with 6 cycles of rituximab in combination with 6 or 26 cycles of ve … Pending
  2025-524283-38-00 5 Relapsed or refractory chronic lymphocytic leukemia
• An International, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Trial on the Effects of EA-230 on the Length of Hospit … Pending
  2025-525053-39-00 5 Coronary artery disease
• A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma (SOLAIRIA-1) Recruiting
  2025-521950-41-00 5 2026-06-05 severe uncontrolled asthma
• Study for frail patients with newly diagnosed multiple myeloma treated with Daratumumab in combination with Teclistamab and Talquetamab. Recruiting
  2024-520433-76-00 4 2026-01-08 Newly Diagnosed Multiple Myeloma
• ASPIRING Recruiting
  2024-516188-10-00 6 2025-10-07 Intracerebral haemorrhage
• A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia … Recruiting
  2024-512753-24-00 5 2025-08-05 Acute Myeloid Leukemia (AML)
• A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with … Recruiting
  2024-513965-38-01 5 2025-06-16 Sjögren's Disease
• A study investigating the effect of adding revumenib to treatment with venetoclax + azacitidine in patients with acute myeloid leukemia (AML … Recruiting
  2024-512733-32-00 5 2025-03-31 Acute Myeloid Leukemia (AML)
• The QUEEN-IVF trial: Quinidine versus verapamil in short-coupled idiopathic ventricular fibrillation: An open-label, randomized crossover pi … Recruiting
  2024-511190-30-00 4 2024-11-25 Short-coupled Idiopathic Ventricular Fibrillation
• Perioperative versus adjuvant FOLFIRINOX for resectable pancreatic cancer: the PREOPANC-3 study Recruiting
  2024-510617-15-00 5 2024-09-06 Non-metastatic resectable pancreatic cancer
• A Phase 3 program evaluating the effect of filgotinib in subjects with active axial spondyloarthritis Recruiting
  2022-501354-10-01 5 2023-06-21 axial spondyloarthritis
• This study is to find out the safety and effectiveness of Epcoritamab together with R-CHOP (rituximab, cyclophosphamide, doxorubicin HCL, vi … Recruiting
  2023-505277-32-00 5 2023-01-26 Diffuse Large B-Cell Lymphoma (DLBCL)
• PROTECx - Pembrolizumab Registry for Outcomes and Treatment Evaluation in Cervical Cancer Recruiting
  2025-522883-34-00 6 2026-06-12 Metastatic cervical cancer
• PUMP-IT RCT: Hepatic arterial infusion PUMP chemotherapy combined with systemic therapy versus systemic therapy alone as Induction Therapy f … Recruiting
  2023-506194-35-00 5 2026-05-22 Colorectal liver metastases
• eValuating the efficacy and safety of InitiatinG depemokImab earLy therApy iN COPD with Type 2 inflammation (VIGILANT) Recruiting
  2025-521108-23-00 5 2026-05-19 Chronic Obstructive Pulmonary Disease
• Clinical Surveillance vs. Anticoagulation for Low-risk Patients with Isolated Subsegmental Pulmonary Embolism: A Multicenter Randomized Plac … Recruiting
  2023-507801-32-00 6 2026-04-22 Isolated Subsegmental Pulmonary Embolism
• A study to learn about how safe BAY 3389934 is, its suitable dose, and how it affects the participants with sepsis and coagulopathy Recruiting
  2024-515635-30-00 3 2026-03-24 Coagulopathy
• Lp(a) lowering study of pelacarsen (TQJ230) with background inclisiran in participants with elevated Lp(a) and established ASCVD Recruiting
  2024-516356-18-00 5 2026-02-17 Atherosclerotic cardiovascular disease (ASCVD)
• Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Platinum Resistant Ovarian Cancer Recruiting
  2024-514822-21-00 5 2025-10-02 Platinum-resistant Ovarian Cancer

Showing 1–24 of 106 trials